30 results found.

Lymphoma, Follicular Clinical Trial using BI 695500; MabThera

Boehringer Ingelheim - Recruiting 18 years or older.
- A Randomized, Double-blind, Parallel-arm, Phase I Study to Evaluate the Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab (MabThera) Induction Immunotherapy as a First-line Treatment in Patients With Low Tumor Burden Follicular Lymphoma.
BI 695500; MabThera

Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymph Clinical Trial using Idelalisib

Gilead Sciences - Recruiting 18 years or older.
- Single-agent CAL-101 for Previously Teated Low-grade Lymphoma: A Phase 1/2 Study of Safety, Efficacy, and Flow-cytometric Assessment of Tumor-cell Signaling Events.
Idelalisib

Lymphoma Clinical Trial using PCI-32765 (Ibrutinib)

Janssen Research & Development, LLC - Recruiting 18 years or older.
- An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma.
PCI-32765 (Ibrutinib)

Lymphoma, Non-Hodgkin Clinical Trial using Rituximab; Lenalidomide; Placebo

Celgene Corporation - Recruiting 18 years or older.
- A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma (The 'AUGMENT' Study).
Rituximab; Lenalidomide; Placebo

Lymphoma Clinical Trial using MabThera/Rituxan; Standard chemotherapy

Hoffmann-La Roche - Recruiting 18 years to 80 years.
- A Single Arm, Multicentre, Phase IIIb Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL).
MabThera/Rituxan; Standard chemotherapy

Non-Hodgkin's Lymphoma Clinical Trial using Mabthera intravenous; MabThera subcutaneous

Hoffmann-La Roche - Recruiting 18 years or older.
- A Two-stage Phase III, International, Multi-center, Randomized, Controlled, Open-label Study to Investigate the Pharmacokinetics, Efficacy and Safety of Rituximab SC in Combination With CHOP or CVP Versus Rituximab IV in Combination With CHOP or CVP in Patients With Previously Untreated Follicular Lymphoma Followed by Maintenance Treatment With Either Rituximab SC or Rituximab IV.
Mabthera intravenous; MabThera subcutaneous

Lymphoma, B-Cell, Non-Hodgkin's Lymphoma Clinical Trial using rituximab [MabThera/Rituxan]; CHOP; CVP; bendamustine

Hoffmann-La Roche - Recruiting 18 years to 80 years.
- A Randomized, Open-label, Multicenter Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a.
rituximab [MabThera/Rituxan]; CHOP; CVP; bendamustine

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Clinical Trial using PCI-32765 (Ibrutinib)

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study.
PCI-32765 (Ibrutinib)

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Clinical Trial using Anti-CD19-CAR Transduced PBL; Fludarabine; Cyclophosphamide; PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 68 years.
- Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With B-cell Lymphoma or Leukemia.
Anti-CD19-CAR Transduced PBL; Fludarabine; Cyclophosphamide; PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)

Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed F Clinical Trial using Pixantrone + Rituximab; Gemcitabine + Rituximab

Cell Therapeutics - Recruiting 18 years or older.
- A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant.
Pixantrone + Rituximab; Gemcitabine + Rituximab

Lymphoma, Non Hodgkin Clinical Trial using rituximab [MabThera/Rituxan]

Hoffmann-La Roche - Recruiting 18 years to 80 years.
- OPEN LABEL, SINGLE-ARM, PHASE IIIb CLINICAL TRIAL TO EVALUATE THE SAFETY OF SWITCHING FROM INTRAVENOUS RITUXIMAB TO SUBCUTANEOUS RITUXIMAB DURING FIRST LINE TREATMENT FOR CD20+ NON-HODGKIN'S FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA..
rituximab [MabThera/Rituxan]

Lymphoma, Follicular Clinical Trial using Ofatumumab; Rituximab

GlaxoSmithKline - Recruiting 18 years or older.
- Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy.
Ofatumumab; Rituximab

Follicular Non-Hodgkin's Lymphoma Clinical Trial using R-CHOP; Observation; Maintenance weekly x4; Ibritumomab Tiuxetan + Maintenance; Standard Maintenance

Fondazione Italiana Linfomi ONLUS - Recruiting 18 years or older.
- A Multicenter, Phase III, Randomized Study to Evaluate the Efficacy of Response-adapted Strategy to Define Maintenance After Standard Chemoimmunotherapy in Patients With Advanced-stage Follicular Lymphoma..
R-CHOP; Observation; Maintenance weekly x4; Ibritumomab Tiuxetan + Maintenance; Standard Maintenance

Follicular Lymphoma Patients (Phase IB), or Follicular and Agress Clinical Trial using Lenalidomide and GA101

The Lymphoma Academic Research Organisation - Recruiting 18 years or older.
- A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive (DLBCL and MCL) B-cell Lymphoma.
Lenalidomide and GA101

Lymphoma, B-Cell Clinical Trial using inotuzumab ozogamicin

Pfizer - Recruiting 18 years or older.
- A Phase 1/2 Study Of CMC-544 Administered In Combination With Rituximab In Subjects With Follicular Or Diffuse Large B-Cell Non-Hodgkin's Lymphoma.
inotuzumab ozogamicin

Follicular Non-Hodgkin's Lymphoma, Nodal Marginal Zone Lymphoma, Clinical Trial using rituximab

Biocad - Recruiting 18 years to 95 years.
- A Multicenter Open-label Randomized Study of BCD-020 (Rituximab, CJSC BIOCAD, Russia) Efficacy and Safety in Comparison With MabThera (F. Hoffmann-La Roche Ltd., Switzerland) in Monotherapy of CD20-positive Indolent Non-Hodgkin's Lymphoma.
rituximab

Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicul Clinical Trial using ibrutinib; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase 2 Trial of Single-Agent Ibrutinib (PCI-32765) in Relapsed or Refractory Follicular Lymphoma.
ibrutinib; laboratory biomarker analysis

Acute Myelogenous Leukemia, Diffuse Large B-Cell Leukemia, Chroni Clinical Trial using BMS-936564 (Anti-CXCR4)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies.
BMS-936564 (Anti-CXCR4)

GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia Clinical Trial using milatuzumab

Immunomedics, Inc. - Recruiting 18 years or older.
- A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies.
milatuzumab

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lym Clinical Trial using alisertib; bortezomib; rituximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma.
alisertib; bortezomib; rituximab; laboratory biomarker analysis

Follicular Lymphoma, B-cell Lymphoma, or Non-Hodgkin's Lymphoma Clinical Trial using Ibrutinib; rituximab

Pharmacyclics - Recruiting 18 years or older.
- A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma.
Ibrutinib; rituximab

Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage Clinical Trial using ofatumumab; bendamustine hydrochloride; bortezomib; laboratory biomarker analysis; positron emission tomography with radiolabeled targeting agents; fludeoxyglucose F 18

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239, IND # 58443) and Bendamustine in Patients With Untreated Follicular Lymphoma.
ofatumumab; bendamustine hydrochloride; bortezomib; laboratory biomarker analysis; positron emission tomography with radiolabeled targeting agents; fludeoxyglucose F 18

Lymphoma Clinical Trial using rituximab

National Cancer Institute (NCI) - Recruiting 18 years or older.
- An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy in Patients With Advanced Stage, Asymptomatic, Non-Bulky Follicular Lymphoma.
rituximab

Diffuse Large B Cell Lymphoma, or Grade IIIB Follicular Lymphoma Clinical Trial using anthropometric measurement

Centre Henri Becquerel - Recruiting 70 years or older.
- Multicentric Prospective Study to Assess the Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma.
anthropometric measurement

Follicular Lymphoma Clinical Trial using Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells

Dana-Farber Cancer Institute - Recruiting 35 years or older.
- A Phase I Trial of Vaccination With Lethally Irradiated Lymphoma Cells Admixed With Granulocyte-Macrophage Colony Stimulating Factor Secreting K562 Cells for the Treatment of Previously Untreated or Relapses Follicular Lymphoma.
Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells

Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Fo Clinical Trial using PI3K inhibitor BKM120; laboratory biomarker analysis

Mayo Clinic - Recruiting 18 years or older.
- A Pilot Study of the PI3K Inhibitor BKM120 in Patients With Relapsed Lymphoma.
PI3K inhibitor BKM120; laboratory biomarker analysis

Follicular Lymphoma Clinical Trial using Rituximab; Lenalidomide; Rituximab - CHOP; Rituximab - CVP; Rituximab - Bendamustine

The Lymphoma Academic Research Organisation - Recruiting 18 years or older.
- A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The 'RELEVANCE' Trial (Rituximab Lenalidomide Versus ANy ChEmotherapy)is Being Conducted as Two Companion Studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the Combined Total of 1000 Patients Enrolled in Both Studies Will be Analyzed..
Rituximab; Lenalidomide; Rituximab - CHOP; Rituximab - CVP; Rituximab - Bendamustine

Follicular Lymphoma, or First Relapse/Progression Clinical Trial using Follicular lymphoma, patient-specific, soluble protein idiotype vaccine

Clinica Universidad de Navarra, Universidad de Navarra - Recruiting 18 years to 65 years.
- Idiotypic Vaccination for Poor-prognosis Follicular Lymphoma Patients in First Relapse.
Follicular lymphoma, patient-specific, soluble protein idiotype vaccine

Follicular Lymphoma Clinical Trial using Y90 Ibritumomab Tiuxetan

Grupo Oncol¢gico para el Tratamiento y el Estudio de los Linfomas - Recruiting 18 years or older.
- Consolidation Treatment With Y90-Ibritumomab Tiuxetan In Patients With High-Risk Follicular Lymphoma With Either Partial Or Complete Response To R-Chop Induction Chemotherapy.
Y90 Ibritumomab Tiuxetan